{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:53:59Z","timestamp":1791536039823,"version":"4.3.4"},"reference-count":34,"publisher":"Wiley","issue":"23-24","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100000650","name":"Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000650","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Statistics in Medicine"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The goal of dose\u2010finding oncology trials is to assess the safety of anti\u2010cancer treatments across multiple doses and to recommend dose(s) for subsequent trials. As patients' outcomes accrue, trialists dynamically recommend new doses for further investigation during the trial. This adaptive decision\u2010making lends itself to Bayesian learning, with Bayesian frameworks increasingly guiding dose recommendations in model\u2010based dose\u2010finding designs, including the Continual Reassessment Method (CRM). However, such approaches introduce increased complexity, not least when additional outcomes are incorporated within designs. Such trial designs require careful prior selection. Directly applying prior calibration methods developed for single outcome model\u2010based trial designs to joint outcome trial designs may introduce unintended bias in dose recommendations, potentially limiting dose exploration and failing to accurately reflect trialists' a priori beliefs. We extend methodology to analytically calibrate priors for model\u2010based joint outcome trial designs with divergence minimisation. Our method offers an analytical and computationally efficient technique. We demonstrate the flexibility of our calibration method relative to existing approaches in ensemble simulation scenarios, and show that calibrating priors in this way delivers improved accuracy and computational efficiency compared with traditional grid search methods. As Bayesian dose\u2010finding trial designs continue to advance, research and guidance on the effective calibration of design parameters is essential to support uptake and ensure optimal performance in practice. This method provides an analytical and intuitive approach to prior calibration, highlighting the importance of rigorous prior calibration in improving model accuracy and dose selection for safer, more effective oncology treatments.<\/jats:p>","DOI":"10.1002\/sim.70746","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:18:57Z","timestamp":1790846337000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Calibration of Priors for Bayesian Model\u2010Based Dose\u2010Finding Trial Designs With Joint Outcomes"],"prefix":"10.1002","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5378-7439","authenticated-orcid":false,"given":"Emily","family":"Alger","sequence":"first","affiliation":[{"name":"Clinical Trial and Statistics Unit Institute of Cancer Research  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8413-6869","authenticated-orcid":false,"given":"Shing M.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Mailman School of Public Health, Columbia University  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8530-035X","authenticated-orcid":false,"given":"Ying Kuen K.","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Mailman School of Public Health, Columbia University  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6715-2514","authenticated-orcid":false,"given":"Christina","family":"Yap","sequence":"additional","affiliation":[{"name":"Clinical Trial and Statistics Unit Institute of Cancer Research  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.2307\/2531628"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_319783"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1017-7"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102020"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1201\/b10783"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774508096474"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.04.030"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2002.00671.x"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4139"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-018-0638-z"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.02.031"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0338307"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2109826"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.09.158"},{"key":"e_1_2_12_16_1","unstructured":"Food and Drug Administration \u201cOptimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases: Guidance for Industry \u201dhttps:\/\/www.fda.gov\/media\/164555\/download. Cited 11 June 2025 2024."},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-07782-z"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102838"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0911494"},{"key":"e_1_2_12_20_1","doi-asserted-by":"crossref","unstructured":"E.BaschandC.Yap \u201cPatient\u2010Reported Outcomes for Tolerability Assessment in Phase I Cancer Clinical Trials \u201d2021.","DOI":"10.1093\/jnci\/djab017"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01625"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8402"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1515\/ijb\u20102022\u20100023"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2014.920873"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.3793"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0389-8"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.2307\/2532905"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103626"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774509105076"},{"key":"e_1_2_12_30_1","unstructured":"K.Cheung \u201cdfcrm: Dose\u2010Finding by the Continual Reassessment Method \u201dR package version 0.2\u20102.1 2019 https:\/\/CRAN.R\u2010project.org\/package=dfcrm."},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/biom.12158"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1214\/21-AOAS1549"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5559"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2004.00218.x"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-51"}],"container-title":["Statistics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/sim.70746","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/sim.70746","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/sim.70746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:41:29Z","timestamp":1791535289000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/sim.70746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":34,"journal-issue":{"issue":"23-24","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/sim.70746"],"URL":"https:\/\/doi.org\/10.1002\/sim.70746","archive":["Portico"],"relation":{},"ISSN":["0277-6715","1097-0258"],"issn-type":[{"value":"0277-6715","type":"print"},{"value":"1097-0258","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2025-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70746"}}